Skip to content

Medical and Health Economic Benefit of Oral Nutritional Supplements (ONS) in Ambulant Patients

Medical and Health Economic Benefit of Oral Nutritional Supplements (ONS) in Ambulant Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02470013
Acronym
ECONONS
Enrollment
160
Registered
2015-06-12
Start date
2014-11-30
Completion date
2018-07-31
Last updated
2019-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malnutrition

Keywords

Malnutrition, Geriatrics, Enteral Nutrition

Brief summary

The aim of this study is to assess the benefit of a 3-month intervention with oral nutritional supplements (ONS) in older ambulant patients with reference to functional limitations and quality of life as well as the consumption of health care resources.

Detailed description

Study participants are assessed upon discharge from the hospital and again after 3 months. Upon discharge all patients receive nutrition counselling with special focus on an energy rich diet. Additionally, the intervention group receives ONS. The investigators hypothesize an improvement in functional limitations and health economic benefits due to the post-hospital nutritional intervention.

Interventions

DIETARY_SUPPLEMENTBalanced, energy dense, moderate protein sip feed

2x 125 ml bottles (equiv. 600 kcal) of Fortimel Compact daily for 3 months in addition to normal eating habits

Sponsors

Pfrimmer Nutricia GmbH, Erlangen , Germany
CollaboratorINDUSTRY
Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 60 years * Informed written consent * Independent community dwelling after discharge * Existing or risk of malnutrition * Normal cognitive status according to Mini-Mental State Examination (MMSE ≥ 24 points) * Life expectancy of \> 3 months according to treating doctor * No severe heart disease (New York Heart Association (NYHA) functional classification of 3+), liver disease (Child Pugh Score = A, B) or kidney insufficiency (glomerular filtration rate \< 30 ml/min) * No chemo or radiation therapy * No derailed diabetes mellitus or metabolic decompensation

Exclusion criteria

* Age \< 60 years * Lack of informed written consent * Dependent living conditions after discharge * No risk of malnutrition * Low cognitive status according to Mini-Mental State Examination (MMSE \< 24 points) * Life expectancy of \< 3 months according to treating doctor * Severe heart disease (New York Heart Association (NYHA) functional classification of 3+), liver disease (Child Pugh Score = C) or kidney insufficiency (glomerular filtration rate \< 30 ml/min) * Chemo or radiation therapy * Derailed diabetes mellitus or metabolic decompensation

Design outcomes

Primary

MeasureTime frame
Change in functional limitations and activities of daily living (single validated questionnaire)Baseline (hospital discharge) and after 3 months

Secondary

MeasureTime frame
Strength Parameter: Knee extension strengthBaseline (hospital discharge) and after 3 months
Quality of life (validated questionnaire)Baseline (hospital discharge) and after 3 months
Body composition (bioelectric impedance analysis)Baseline (hospital discharge) and after 3 months
Functional Parameter: timed up & goBaseline (hospital discharge) and after 3 months
Strength Parameter: Hand grip strengthBaseline (hospital discharge) and after 3 months
Functional Parameter: lung functionBaseline (hospital discharge) and after 3 months
Functional Parameter: gait analysisBaseline (hospital discharge) and after 3 months
Consumption of health care resources (questionnaire) and cost analysisFrom baseline (hospital discharge) during subsequent 3 months
Functional Parameter: stair climbingBaseline (hospital discharge) and after 3 months

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026